Leukotriene B₄ amplifies NF-κB activation in mouse macrophages by reducing SOCS1 inhibition of MyD88 expression

Carlos H. Serezani,¹ Casey Lewis,¹ Sonia Jancar,² and Marc Peters-Golden¹

¹Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Michigan Health System, Ann Arbor, Michigan, USA. ²Department of Immunology, Institute of Biomedical Science IV, University of São Paulo, São Paulo, Brazil.

Activation of NF-κB and 5-lipoxygenase–mediated (5-LO–mediated) biosynthesis of the lipid mediator leukotriene B₄ (LTB₄) are pivotal components of host defense and inflammatory responses. However, the role of LTB₄ in mediating innate responses elicited by specific TLR ligands and cytokines is unknown. Here we have shown that responses dependent on MyD88 (an adaptor protein that mediates signaling through all of the known TLRs, except TLR3, as well as IL-1β and IL-18) are reduced in mice lacking either 5-LO or the LTB₄ receptor BTL1, and that macrophages from these mice are impaired in MyD88-dependent activation of NF-κB. This macrophage defect was associated with lower basal and inducible expression of MyD88 and reflected impaired activation of STAT1 and overexpression of the STAT1 inhibitor SOCS1. Expression of MyD88 and responsiveness to the TLR4 ligand LPS were decreased by Stat1 siRNA silencing in WT macrophages and restored by Socs1 siRNA in 5-LO−/− macrophages. These results uncover a pivotal role in macrophages for the GPCR BLT1 in regulating activation of NF-κB through Stat1-dependent expression of MyD88.

Introduction

Inappropriate inflammatory responses contribute to many pathological conditions, including autoimmunity diseases, asthma, chronic obstructive pulmonary disease, and atherosclerosis. A central feature of inflammation is leukocyte activation, which requires coordination among numerous receptors, signaling pathways, and mediators. TLRs and cytokine receptors drive inflammatory programs in macrophages (1). In addition to sensing microbial products, TLRs sense endogenous danger signals produced during tissue injury. These include extracellular matrix components, such as hyaluronic acid and biglycan, as well as intracellular proteins, including high-mobility group box 1 (1).

TLR family members and the IL-1β receptor (IL-1R) share a conserved cytoplasmic Toll–IL-1R (TIR) domain that binds adaptor proteins, including myeloid differentiation factor 88 (MyD88). MyD88 mediates signaling through all of the known TLRs except TLR3, although its importance for individual TLRs varies (2). Although it is similarly crucial for initiating signaling responses to IL-1β and certain cytokines, such as IL-18, MyD88 does not mediate responses to other cytokines, such as TNF-α (3). MyD88 is necessary for host defense against a variety of experimental infections (4), but also promotes development of atherosclerosis in apoE−/− mice as well as neutrophil recruitment and myocardial injury following ischemia-reperfusion (5); autoimmune responses, diabetes, and colitis (6); and familial Mediterranean fever (7). MyD88 expression can be upregulated beyond its basal level by proinflammatory mediators, including IL-6 (8) and the phorbol ester PMA (9) as well as LPS, IFN-α, CpG-DNA, and IFN-γ (9, 10).

TLR-mediated responses are characterized both by activation of the pivotal transcription factor NF-κB (11) and by synthesis of the 5-lipoxygenase–derived (5-LO–derived) lipid mediator leukotriene B₄ (LTB₄) (Figure 1A and ref. 12). The latter, acting via its high-affinity GPCR BLT1, is best known as a leukocyte chemoattractant but is also a potent enhancer of leukocyte functions, including cytokine secretion and microbial phagocytosis and killing (13). Like MyD88, LTB₄ has also been implicated in antimicrobial defense as well as a variety of inflammatory disease states, such as atherosclerosis, ischemia-reperfusion injury, and immune responses (12). 5-LO metabolites have been suggested to participate in vivo and in vitro LPS responses (14), but these reports were limited by the off-target effects of the pharmacologic inhibitors used (15) and by ambiguity regarding the specific 5-LO products required for TLR responses (14, 16–18). The role of specific 5-LO metabolites and receptors in various TLR- and cytokine receptor–mediated responses is therefore poorly understood. Here we demonstrate that LTB₄ synthesis and signaling via BLT1 are necessary for optimal MyD88 expression and NF-κB activation in macrophages in vitro and in vivo and identify the operative molecular mechanisms by which LTB₄ amplifies NF-κB activation.

Results

5-LO metabolites are required for in vitro and in vivo MyD88-dependent macrophage responses. LPS responses are mediated via TLR4; although signaling from this receptor is dependent on both adaptor proteins MyD88 and TRIF, other TLRs and cytokine receptors use either MyD88 or TRIF to elicit cellular responses (19). To evaluate whether 5-LO metabolites are required for NF-κB activation, as well as the MyD88 dependence of any such requirement, we stimulated elicited peritoneal macrophages from WT and 5-LO−/− mice for 24 hours with the MyD88-dependent agonists LPS, peptidoglycan (PGN), and IL-1β with the MyD88-independent agonists poly(I:C) and TNF-α (2), then measured the secretion of proinflammatory molecules known to be dependent on NF-κB activation (20). All of the TLR and cytokine receptor agonists used stimulated the generation of the NF-κB–dependent gene products RANTES, IL-6, and NO (measured as nitrite) (Figure 1, B–D). Compared with WT cells, 5-LO−/− macrophages exhibited a marked reduction in
mediator generation in response to MyD88-dependent agonists, but no such reduction in response to MyD88-independent agonists. LTB4 itself was also capable of promoting the release of RANTES and IL-6, particularly in 5-LO–/– cells (Supplemental Figure 1, A and B; supplemental material available online with this article; doi:10.1172/JCI43302DS1). A similar pattern of LTB4 dependence of LPS, but not poly(I:C), responses was observed in 2 populations of resting macrophages, namely bone marrow–derived macrophages (BMDMs) and resident peritoneal macrophages (Supplemental Figure 2, A and B, and data not shown).

Since these data indicated that 5-LO metabolites are required for optimal MyD88-dependent generation of proinflammatory molecules in vitro, we investigated their in vivo importance in LPS-induced shock. Whereas 50% of WT mice died from i.p. LPS injection, only 10% of 5-LO–/– mice died from the same endotoxin dose (P < 0.05; Figure 1E). In contrast, WT and 5-LO–/– mice exhibited similar mortality, in excess of 80%, after i.p. challenge with the MyD88-independent agonist TNF-α. We next sought to determine whether the lower mortality in LPS-treated 5-LO–/– animals correlates with levels of NF-κB–dependent cytokines in the serum and peritoneal lavage fluid measured 6 hours after LPS challenge. Both serum (Figure 1, F and G) and peritoneal fluid (Supplemental Figure 1, C and D) levels of RANTES and IL-6 were significantly lower in 5-LO–/– mice than WT mice following LPS injection, whereas TNF-α injection induced similar levels of these cytokines in the serum from both genotypes. We also investigated serum levels of IL-10—a cytokine whose expression depends on transcription factors other than NF-κB, including CREB and Sp1/Sp3 (21, 22)—in order to evaluate the specificity of leukotriene (LT) dependence for NF-κB activation. In contrast to the NF-κB–dependent cytokines, IL-10 production was no different in 5-LO–/– than in WT mice challenged with LPS (or TNF-α; Figure 1H). Taken together, these results suggest that production of NF-κB–dependent cytokines as well as systemic inflammatory responses integral to lethal shock that are driven by MyD88-dependent agonists depend on 5-LO metabolites.

5-LO metabolites are required for MyD88-dependent NF-κB activation. We sought to more directly determine the requirement of 5-LO for TLR-induced NF-κB activation. ELISA assays demonstrated DNA
binding activity of the NF-κB p65 subunit in WT macrophages stimulated with the TLR4 agonist LPS, the TLR2 agonist Pam3Cys, and the TLR3 agonist poly(I:C); binding was detectable as early as 30 minutes and maximal at 24 hours (Figure 2A). 5-LO−/− macrophages exhibited markedly blunted p65 binding relative to WT cells at all time points in response to LPS and Pam3Cys, although p65 binding in response to poly(I:C) was intact (Figure 2A). In order to more comprehensively evaluate the MyD88 dependence of NF-κB...
binding to DNA, and to verify binding of transcriptionally active p65/p50 heterodimers, we used a larger panel of MyD88-dependent and -independent agonists in ELISA assays of p50 DNA binding. As observed for p65, binding activity of p50 in 5-LO−/− macrophages at 24 hours was markedly diminished in response to the MyD88-dependent agonists LPS, PGN, and IL1-β, but not to the MyD88-independent agonists TNF-α and poly(I:C) or to LTB4 itself (Figure 2B). These findings were also confirmed by assessing nuclear translocation of the NF-κB p50 subunit by immunofluorescence microscopy (Figure 2C) and by quantifying the nuclear colocalization of p50 with DAPI immunofluorescence using the Image J plug-in Jacop (Figure 2D and ref. 23). Poly(I:C) enhanced p50 nuclear translocation in elicited macrophages from both WT and 5-LO−/− mice. However, LPS-induced p50 translocation was attenuated in macrophages from 5-LO−/− animals, and the same was true for p65 translocation (Supplemental Figure 3A). Phosphorylation of the cytosolic inhibitor IκBα initiates its degradation and is required for subsequent NF-κB activation (24). We therefore assessed IκBα phosphorylation in WT and 5-LO−/− macrophages following TLR stimulation. Activation of IκBα in WT macrophages occurred as soon as 5 minutes after LPS challenge, peaked at 15 minutes, and persisted for up to 60 minutes (Supplemental Figure 3B). In 5-LO−/− macrophages, onset of activation was delayed, and the magnitude and duration of activation were also diminished. Stimulation with a panel of TLR agonists confirmed that, as observed for other response parameters, IκBα phosphorylation was attenuated in 5-LO−/− cells exclusively in response to MyD88-dependent stimuli (Supplemental Figure 3C). We confirmed the requirement of 5-LO metabolism in LPS-induced IκBα phosphorylation and NO generation by pretreating WT cells with the 5-LO inhibitor AA-861 for 48 hours (Supplemental Figure 4C). In WT cells, LPS- or poly(I:C)-treated macrophages treated with the 5-LO inhibitor AA-861 for 48 hours. Data are representative of 3 experiments. (E) Myd88 mRNA decay in WT and 5-LO−/− macrophages incubated for 24 hours as indicated. Immunoblot results are from 2–3 independent experiments (relative MyD88 density shown by numbers beneath). Lanes were run on the same gel but were noncontiguous (white line). (F) Nitrite production in WT and 5-LO−/− macrophages pretreated for 24 hours with or without LTB4, followed by LPS for another 24 hours. Data are representative of 3 experiments. *P < 0.05 versus control; #P < 0.05 versus WT; $P < 0.01 versus non–LTB4-treated stimulated WT; $P < 0.01 versus LPS or IL-1β alone.

Figure 3

LTB4 is required for MyD88 expression in phagocytes. (A) MyD88, TIRAP, TRIF, and TIRP protein expression in WT macrophages and in 5-LO−/− and BLT1−/− macrophages treated for 24 hours with or without LTB4. (B) Densitometry of MyD88 protein in 5-LO−/− and BLT1−/− macrophages. (C) Myd88 mRNA expression in 5-LO−/− and BLT1−/− macrophages treated as in A. (B and C) Data are representative of 3 experiments, performed in triplicate; values are relative to control WT macrophages (dashed line). *P < 0.05 versus WT; **P < 0.01 versus untreated 5-LO−/−. (D) MyD88 protein expression in resident peritoneal (PM), alveolar (AM), and splenic (SM) macrophages as well as splenic DCs, T and B lymphocytes, and lung fibroblasts from WT and 5-LO−/− mice. Data are representative of 3 experiments. (E) Myd88 mRNA decay in WT and 5-LO−/− macrophages harvested after treatment with actinomycin D (2.5 mg/ml). Data are from 3 experiments in triplicate; values are relative to untreated macrophages from both genotypes. (F) MyD88 protein expression in resident peritoneal (PM), alveolar (AM), and splenic (SM) macrophages, as well as splenic DCs, T and B lymphocytes, and lung fibroblasts from WT and 5-LO−/− mice. Data are representative of 3 experiments. (G) Myd88 protein in WT and 5-LO−/− macrophages incubated for 24 hours as indicated. Immunoblot results are from 2–3 independent experiments (relative MyD88 density shown by numbers beneath). Lanes were run on the same gel but were noncontiguous (white line). (G) Nitrite production in WT and 5-LO−/− macrophages pretreated for 24 hours with or without LTB4, followed by LPS for another 24 hours. Data are representative of 3 experiments. *P < 0.05 versus control; $P < 0.01 versus non–LTB4-treated stimulated WT; $P < 0.01 versus LPS or IL-1β alone.
arachidonic acid also leads to the generation of reactive oxygen species (25), and NF-κB activation is known to be sensitive to oxidant tone (15). Thus, we sought to verify that LPS-induced IkBα phosphorylation in WT macrophages depends on lipid metabolites of 5-LO and to determine the relative roles of LTB4 versus CysLTs in this response. As an initial approach to addressing these questions, we pretreated WT cells for 48 hours with antagonists to their respective high-affinity GPCRs, BLT1 (CP105,696) and CysLT1 (MK571). Only the BLT1 antagonist prevented LPS-induced IkBα phosphorylation and NO secretion (Supplemental Figure 4, C and D). Exogenous LTB4 also synergized with LPS to dose-dependently enhance iNOS expression and NO production (data not shown). These data strongly suggest that LTB4 is the main 5-LO product that administration of LTB4 augmented nuclear p50 translocation in response to LPS, but not poly(I:C) (Figure 2F). A similar selective impairment of BLT1−/− macrophages in NO production in response to LPS, but not poly(I:C) (Figure 2H), reinforced the conclusion that BLT1 signaling is required for MyD88-dependent NF-κB activation.

We next sought to assess the role of LTB4 in NF-κB activation in an in vivo setting and in response to a genuine microbial stimulus rather than a purified or synthetic TLR ligand. We thus infected WT and 5-LO−/− mice intranasally with the important respiratory pathogen Streptococcus pneumoniae, which is recognized mainly by TLR2 (26); administered aerosolized LTB4, or vehicle control 24 hours later; and assessed p50 localization by immunofluorescence microscopic examination of lung cells obtained by lavage 24 hours thereafter (Supplemental Figure S5). Compared with that observed in uninfected animals, p50 nuclear translocation was increased in alveolar macrophages from infected and vehicle-treated WT, but not 5-LO−/− mice. Administration of LTB4 by aerosol augmented nuclear p50 staining in macrophages from both genotypes, restoring the p50 translocation response in 5-LO−/− mice to the level observed in infected WT animals. Consistent with these results, we recently reported that administration of LTB4 using this protocol also enhances lung bacterial clearance in 5-LO−/− animals (27). Interestingly, we did not
observe p50 nuclear translocation in neutrophils from either genotype in the absence or presence of aerosolized LTB₄ (data not shown). Thus, both pharmacologic and genetic approaches demonstrated that LTB₄ generation and BLT1 signaling are essential for optimal MyD88-dependent activation of NF-κB in vivo and in vitro.

**LTB₄ is required for MyD88 expression in phagocytes.** Because downstream signaling pathways linking various adaptors to NF-κB activation are largely redundant, yet findings in Figures 1 and 2 indicated an impairment in 5-LO−/− macrophage responses that was limited to particular agonists, mechanistic exploration was focused on proximal pathway components. 5-LO−/− macrophages manifested no reduction in the expression levels of TLR4 or CD14 (data not shown), consistent with the findings above that impaired responses in these cells extended to MyD88-dependent agonists besides LPS. We next determined whether elicited macrophages from 5-LO−/− mice exhibit altered expression of MyD88 or of the other TLR adaptors TIRAP, TRIF, and TIRP compared with WT macrophages. The LT-deficient cells manifested decreased basal MyD88 protein and mRNA expression. Pretreatment of WT macrophages with the 5-LO inhibitor AA-861 for 48 hours also decreased basal MyD88 expression (Supplemental Figure 4A), and preliminary studies verified a similar effect in human monocytes as well (data not shown). Pretreatment for 48 hours with a BLT1 antagonist, but not a CysLT1 antagonist, also decreased basal MyD88 expression in WT elicited macrophages (Supplemental Figure 4A). The reduction in MyD88 expression in 5-LO−/− macrophages was restored to levels above WT by incubation with exogenous LTB₄ in a time-dependent manner (Figure 3, A–C, and Supplemental Figure 6). Furthermore, pretreatment of 5-LO−/− macrophages with LTB₄ for 24 hours fully restored both LPS and IL-1β responsiveness in these cells, as reflected by NO generation (Figure 3G). Only a modest enhancement of MyD88 expression was effected by provision of exogenous LTD₄ (Supplemental Figure 4B). Similar reductions in MyD88 protein and mRNA levels were also observed in BLT1−/− macrophages, but, as would be expected in the absence of its cognate receptor, reductions in the adaptor could not be overcome by addition of LTB₄ (Figure 3, A–C). No decrease in expression of any of the other adaptors was noted in 5-LO−/− versus WT macrophages; however, TRIF expression was consistently higher in 5-LO−/− than WT macrophages (Figure 3A). While this suggests a possible compensatory mechanism in 5-LO−/− macrophages, its functional significance is uncertain, since levels of mediators generated in response to poly(I:C) by these cells were not consistently higher than in WT macrophages.

MyD88 deficiency in 5-LO−/− animals was restricted to tissue phagocytes, including resident peritoneal, alveolar, and spleen macrophages as well as spleen DCs and BMDMs, but was not observed in T or B lymphocytes or lung fibroblasts (Figure 3D). This cell-specific pattern of 5-LO dependence for MyD88 expression correlates nicely with the well-known robust capacity for LTB₄ synthesis of phagocytes (13). Since levels of Myd88 mRNA are dictated by both transcription (28) and degradation (29), we compared its decay in WT and 5-LO−/− macrophages. At various time points following addition of actinomycin D to block the formation of new transcripts, cells were processed for real-time RT-PCR analysis. No difference in mRNA stability was observed between 5-LO−/− and WT macrophages (Figure 3E), which suggests that reduced Myd88 mRNA in 5-LO−/− cells reflects a transcriptional defect.
MyD88 expression can be potentiated above basal levels by treatment with inflammatory mediators (2). We therefore compared the effects of proinflammatory molecules known to increase MyD88 expression on levels of this adaptor in 5-LO−/− and WT macrophages (Figure 3F). Both MyD88-dependent and -independent agonists augmented MyD88 protein expression in WT cells, but this response was markedly blunted in 5-LO−/− macrophages. Of the mediators tested, only exogenous LTβ4 was able to increase MyD88 expression to a considerable degree in cells from LT-deficient mice, attesting to the specific importance of LTβ4 in increasing MyD88 expression. Taken together, our findings show that LTβ4, but not CysLTs, is required for upregulating transcriptional programs required for both basal and induced MyD88 expression.

Enhanced JAK/STAT1 activation mediates LTβ control of MyD88 expression. STAT1 is a key transcription factor governing MyD88 expression (28). STAT1 is well known to be activated by IFNs (30), but little is known about its activation by macrophage GPCRs. Because of the important regulatory influence of LTβ on MyD88 gene expression, we sought to determine whether LTβ4/BLT1 signaling is required for STAT1 activation. Compared with WT macrophages, 5-LO−/− cells displayed lower basal phosphorylation of STAT1 at Tyr701, a residue important for its nuclear translocation (31), and the degree of phosphorylation was enhanced in cells of both genotypes by LTβ4 treatment (Figure 4A and B). No such difference between the genotypes was noted in STAT1 phosphorylation at Ser727 (Figure 4A and data not shown), a residue important for DNA binding activity (31). STAT1 phosphorylation at Tyr701 was also evaluated in WT macrophages pretreated with a 5-LO inhibitor as well as CysLT1 or BLT1 antagonists. Basal phosphorylation was diminished in response to the 5-LO inhibitor and the BLT1 antagonist, but not the CysLT1 antagonist (Supplemental Figure 7). These data suggest that the impairment in basal STAT1 phosphorylation at Tyr701 is likely a critical determinant of MyD88 deficiency in cells incapable of LTβ4 synthesis and signaling, but exclude a role for CysLTs in this process. As a complementary approach, we determined nuclear STAT1 activity in WT and 5-LO−/− as well as BLT1−/− macrophages. Both 5-LO−/− and BLT1−/− macrophages exhibited lower STAT1 activity than their corresponding WT macrophages. Exogenous LTβ4 enhanced STAT1 activation in WT and 5-LO−/− macrophages, but not in BLT1−/− cells (Figure 4, C and D). To address the importance of STAT1 in mediating MyD88 expression, we used siRNA to knock down Stat1 and achieved a 70% decrease in Stat1 mRNA compared with control siRNA (Figure 4E). Stat1 knockdown decreased Myd88 mRNA expression by 45%. This decrease in MyD88 expression following STAT1 knockdown correlated with a lower capability of WT macrophages to produce NO, RANTES, and IL-6 upon LPS stimulation (Figure 4, F–H), thus recapitulating the phenotype observed in 5-LO−/− and BLT1−/− cells, which themselves expressed decreased MyD88.

Tyrosine phosphorylation and activation of STAT1 are mediated by the tyrosine kinases JAK1/2 and Tyk2 (32). 5-LO−/− and BLT1−/− macrophages exhibited less basal activation of JAK2, but not JAK1 or Tyk2, than did their respective WT cells, and exogenous LTβ4 enhanced its phosphorylation in 5-LO−/−, but not BLT1−/−, macrophages (Figure 5A). To verify that LTβ4-induced activation of JAK2 is required for STAT1 phosphorylation, we used pharmacological inhibitors of JAK2 activation, AG490 (33) and JAK2 inhibitor 1 (2-[1,1-Dimethylethyl]-9-fluoro-3,6-dihydro-7H-benz[h]-imidaz[4,5-f]isoquinolin-7-one, P6, Pyridone 6; ref. 34), in WT macrophages. JAK2 inhibition abolished LTβ4-induced STAT1 phosphorylation at Tyr701 (Figure 5B).

We have previously shown that the effects of BLT1 on resident alveolar macrophage antimicrobial functions are mediated primarily by Gq signaling (35). However, it is not known whether Gq signaling is required for BLT1 effects, including JAK2/STAT1 activation, in elicited peritoneal macrophages. The role of Gq proteins was determined by pretreating WT elicited macrophages with the Gq inhibitor pertussis toxin (PTX; ref. 35). PTX prevented LTβ4-induced phosphorylation of both JAK2 and STAT1, implicating Gq signaling in these events (Figure 6A). We also studied the role of Gq signaling in determining basal as well as LTβ4-enhanced Myd88 expression. PTX decreased basal MyD88 expression and...
Indeed, both approximately 50% over the interval between 4 and 24 hours (Figure 6B), Gcologic 5-LO inhibition and BLT1 antagonism increased SOCS1 phages (Figure 7, A and B). No difference in mRNA levels of other phages, and LTBα-activated JAK2/STAT1 activation, and hence MyD88 expression. Together, these data show that the increase of SOCS1 expression in cells from 5-LO–/– mice is in fact responsible for their decreased MyD88 expression and NF-κB–dependent responses, we tested the effects of Soc1 knockdown using siRNA. Soc1 siRNA decreased Soc1 mRNA expression in WT and 5-LO–/– macrophages by approximately 70% (Figure 8A), but had no effect on Soc3 expression (data not shown). A control siRNA had no significant effect on Soc3 expression. Importantly, silencing of Soc1, but not Soc3, enhanced MyD88 protein and mRNA expression in WT and especially 5-LO–/– macrophages (Figure 8, B and C) and completely restored the generation of NO, RANTES, and IL-6 by LPS-stimulated 5-LO–/– macrophages to a level comparable to that of WT cells treated with control siRNA (Figure 8, E–G). Collectively, our findings showed that LTB4 increases Soc1 mRNA degradation, which allows STAT1-mediated MyD88 expression and hence optimal TLR-induced secretion of proinflammatory mediators.

Discussion

Here we demonstrate a nonredundant regulatory role of the lipid mediator LTβ1 in amplifying macrophage MyD88 expression, which thus permits enhanced TLR/IL-1R–dependent NF-κB activation (Figure 8H). To our knowledge, this is the first demonstration of an essential role for a GPCR in MyD88-dependent responses. Our results specifically showed that (a) LTB4/LTβ1 signaling is required for MyD88-dependent NF-κB activation and production of proinflammatory molecules in vivo and in macrophages in vitro; (b) LTB4/LTβ1 is required for basal and inducible MyD88 gene
expression; (c) the MyD88 transcription factor STAT1 is activated by LTβ in a manner dependent on Goi activation and JAK2 phosphorylation; (d) Stat1 silencing prevents MyD88 expression and LPS responsiveness; (e) LTβ/BLT1 effects are mediated by enhanced degradation of mRNA encoding SOCS1, an important brake on the activation of JAK2 and STAT1; and (f) Socs1 knockdown restores MyD88 expression and enhacement of MyD88-dependent NF-κB activation. The fact that this regulatory influence of LTβ/BLT1 was manifested in 2 different background mouse strains (Sv/129 for 5-LO−/− and C57BL/6 for BLT1−/− animals) underscores its generalizability. Moreover, 2 different models demonstrated the in vivo significance of this form of regulation. In the first, 5-LO−/− mice were protected from endotoxin shock and concomitant generation of inflammatory mediators. In the second, alveolar macrophage NF-κB activation during pneumococcal pneumonia was impaired in 5-LO−/− mice, but restored by intrapulmonary administration of LTβ.

Since both BLT1 and TLRs are pivotal drivers of inflammatory responses, cross-talk between these 2 classes of receptors is not unexpected. Indeed, TLR ligands have been shown to promote LT biosynthesis (37, 38). Furthermore, both LTβ (39) and CysLTs (40) have themselves been reported to activate NF-κB in specific cells and contexts. However, whether 5-LO metabolites influence TLR responses, whether they are in fact necessary for TLR responses, and which specific 5-LO metabolites exert such actions and by what molecular mechanisms, are not well understood. Here, using both genetic and pharmacological approaches, we showed that MyD88-dependent NF-κB activation in macrophages depends on LTβ biosynthesis and BLT1 signaling in both in vitro and in vivo settings. We have shown that the other major class of 5-LO metabolite, the CysLTs, do not exert effects on SOCS1, STAT1, and MyD88, emphasizing the specific and nonredundant role of LTβ in regulating MyD88-dependent responses in macrophages.
MyD88 expression in macrophages can be augmented above basal levels upon stimulation with proinflammatory molecules such as LPS (9), IFNs (9, 10), IL-6 (8), TNF-α (9), and IL-12 (10). Notably, LTβR was required not only for constitutive, but also for inducible, expression of MyD88. Also striking was the fact that the upregulatory influence on MyD88 expression and TLR responsiveness was observed not only following the addition of exogenous LTβ, but also under basal conditions, in which levels of constitutive endogenous LTβ generation would be expected to be quite low. Basal release of LTβ by elicited peritoneal macrophages from WT animals over 90 minutes was approximately 100 pg/ml, which is equivalent to 0.5 nM. This concentration is indeed sufficient to activate BLT1, since we have shown that LTβ amplifies AM antimicrobial functions at concentrations as low as 0.01 nM (35).

Control of MyD88-dependent responses by LTβR/BLT1 appears to be limited to cells that express abundant 5-LO and BLT1, including tissue phagocytes, and is not operative in lymphocytes and fibroblasts, which do not. It therefore dictates inflammatory responses in the cells that are the pivotal first responders in innate immune processes. Studies with PTX revealed that Gαi signaling downstream from BLT1 was essential for LTβ-mediated MyD88 expression. Little is known about the role of JAK/STAT in the physiological or pathophysiologic functions of GPCRs. Gαi signaling triggered by angiotensin II has been reported to enhance JAK2 activation in a manner dependent on the tyrosine kinase Src (41). As we have previously demonstrated that LTβ enhances Src activation in macrophages (42), we speculate that Src could be the upstream kinase responsible for tyrosine phosphorylation of JAK2 and initiation of STAT1-dependent MyD88 transcription. The lower basal phosphorylation of tyrosine residues on both JAK2 and STAT1 in 5-LO−/− macrophages led us to consider the possibility that LTβ deficiency increases the expression of SOCS proteins, the negative regulators of JAK/STAT signaling (36). Indeed, 5-LO−/− and BLT1−/− cells manifested significantly higher mRNA and protein expression of SOCS1 (but not of other SOCS family members), which was reduced back to WT levels by addition of LTβ4 in BLT1+ cells. The finding that PTX increased Socs1 expression in WT macrophages (Figure 7C) while concomitantly reducing Myd88 expression (Figure 6B) suggests that SOCS1 expression in these cells may be enhanced by cyclic AMP. Although to our knowledge, regulation of SOCS1 by cyclic AMP has not previously been established, this possibility is consistent with a report that prostaglandin E2, via Gαs-coupled receptor–derived cyclic AMP, increased SOCS3 expression (43, 44). In contrast to this paradigm, increased expression of SOCS1 and SOCS3 has previously been reported in response to ligation of chemotaxant receptors other than BLT1, including CXCXR1/2 by CXCL8/IL-8 and FPR-1 by IMLP (45). The conflicting nature of these data suggests that cyclic AMP regulation of SOCS proteins is context dependent. We found that endogenous and exogenous LTβ reduced Socs1 mRNA primarily by increasing its rate of degradation; to our knowledge, this is the first demonstration of a GPCR regulating Socs1 mRNA stability. Among the complex determinants of mRNA stability are the nucleotide sequence itself (46), destabilizing zinc-finger proteins (47), and microRNAs (46). Further studies will be necessary to elucidate the mechanisms by which LTβ4/BLT1 signaling regulates Socs1 mRNA stability.

Our findings have direct translational importance, as pharmacologic 5-LO inhibitors or BLT1 antagonists that are currently available or under development would be expected to reduce macrophage MyD88 expression and attenuate the excessive NF-κB activation characteristic of a variety of inflammatory diseases. These include activation of TLR4 by danger signals released during tissue injury (48) or of unchecked IL-1R activation in autoinflammatory conditions (7). At the same time, however, acquired states of LTβ deficiency, such as HIV infection and malnutrition (13), would be expected to limit NF-κB activation and thereby compromise innate immune defense against microbial pathogens. Indeed, the recent finding that alveolar macrophages from HIV− individuals exhibit a signaling defect limited to MyD88-dependent TLRs (49) could potentially be explained by the findings reported herein, together with the LTβR deficiency previously described for these cells (13). States of immunosuppression such as these might be overcome by administration of exogenous LTβ4.

**Methods**

*Animals.* 8-week-old female 5-LO−/− (129-Alox5tm1Fun; ref. 50) and strain-matched WT sv/129 mice, and BLT1−/− (B6.129S4-Ltb4r1tm1Adl/J; ref. 51) and strain-matched WT C57BL/6 mice (The Jackson Laboratory), were treated according to NIH guidelines for the use of experimental animals, with the approval of the University of Michigan Committee for the Use and Care of Animals.

*Cell harvest.* Macrophages were harvested from the peritoneal cavities of mice by lavage with PBS 4 days after the injection of 2 ml of 3% thioglycollate, as described previously (52).

*Purification of leukocyte populations.* Purification of spleen macrophages, DCs, T cells, and B cells was accomplished using magnetic beads conjugated to CD11b, CD11c, TCRβ, and CD19, respectively, as described by the manufacturer (Miltenyi). Alveolar macrophages (35) and lung fibroblasts (53) were isolated as described previously.

*Macrophage stimulation.* Cells were stimulated with LPS (from E. coli serotype 0111:B4; 100 ng/ml), PGN (1 μg/ml), Pam3Cys (2 μg/ml), or poly(I:C) (50 μg/ml; all from Invivogen); IL-1β (2 ng/ml; Novus Biologicals); TNF-α (2 ng/ml; Biosource); and LTβ4 (10 nM) or LTb4 (100 nM; both from Biosol) for the time periods indicated in the figure legends.

*Immunoblotting.* Western blots were performed as previously described (52). Protein samples were resolved by SDS-PAGE, transferred to a nitrocellulose membrane, and probed with commercially available primary antibodies against MyD88, TRIF, TIRP, SOCS1 (all 1:500, Abcam); p65, TIRAP, phosphorylated IκBα, p50, p65 (all 1:500, Santa Cruz); Tyr701- and Ser727-phosphorylated as well as total STAT1, STAT3, and JAK2; and phosphorlated JAK2 (Tyr1007/1008), JAK1 (Tyr1022/1023), Tyrk (Tyr1052/1053), and STAT3 (Tyr705) (all 1:1,000; Cell Signaling); and α-actin (1:10,000; Sigma-Aldrich). Densitometric analysis was as described previously (35).

*Immunofluorescence microscopy and image analysis.* Macrophages adhered on coverslips were stimulated with LPS or poly(I:C) for 24 hours (42). In other experiments, leukocytes were obtained from the lung lavage fluid of mice infected with S. pneumoniae and subsequently treated with aerosolized vehicle or LTβ4 24 hours after infection. The NF-κB p50 or p65 subunit was detected by incubation with rabbit anti-mouse antibody (1:200 dilution) for 60 minutes. Mounts were washed 3 times with 1% BSA-PBS, and rhodamine-conjugated goat anti-rabbit secondary (1:200; Invitrogen) was added for 1 hour at 37°C. Fluorescence was visualized with a Nikon Labophot 2 microscope equipped for epifluorescence at ×400 objective magnification. The extent of colocalization between NF-κB p50 and nuclear DAPI was quantitated using the Jacop plug-in for Image J (23). The background of the collected images was corrected by the Image J rolling ball algorithm plug-in. The specific algorithm used was based on the Manders overlap coefficient (23), which ranges from
Nitrite, the stable oxidized derivative of NO, was determined using the Griess reaction (52).

RNA isolation and semiquantitative real-time RT-PCR. RNA from cultured cells was isolated using the RNeasy Mini Kit (Qiagen) according to the manufacturer’s instructions, and real-time RT-PCR was performed as previously described (54). To determine the decay of Myd88 and Socs1 mRNA, WT and S-LO-/- macrophages were treated with or without 2.5 μg/ml actinomycin D (Sigma-Aldrich) in the presence or absence of exogenous LTB4, and the amount of mRNA was determined after harvesting at different time points. Socs1 or Myd88 mRNA were normalized to β-actin, and the respective WT control was set to 100%. Percentages were plotted against time, and decay curves were calculated.

RNA interference. RNA interference was performed according to a protocol provided by Dharmacon. WT and S-LO-/- macrophages were transfected using DharmaFECT 1 reagent with 30 nM of nonspecific control or specific siRNAs. After 48 hours of transfection, macrophages were harvested for mRNA or protein analysis or treated with LPS for 24 hours to analyze NO, RANTES, and IL-6 secretion.

NF-κB p50, NF-κB p65, and STAT1 activity were assayed using transcription factor ELISAs for NF-κB p50 and p65 subunits (Panomics) as well as STAT1 (Panomics), according to the manufacturer’s instructions.

S. pneumoniae infection. S. pneumoniae serotype 3, 6, 303 (ATCC) was grown, and mice were infected, as described previously (27).

Acknowledgments

We thank members of the Peters-Golden laboratory and Ana Paula Moreira for their thoughtful input. This work was supported by NIH grant HL058897 (to M. Peters-Golden); by an American Lung Association Senior Postdoctoral Research Fellowship, an American Heart Association Career Development Award, and NIH grant K99HL103777 (to C.H. Serezani); and by FAPESP (to S. Jancar).

Received for publication September 16, 2010, and accepted in revised form November 3, 2010.

Address correspondence to: Marc Peters-Golden, 6301 MSRB III, 1150 W. Medical Center Drive, University of Michigan Health System, Ann Arbor, Michigan 48109-5642, USA. Phone: 734.763.9077; Fax: 734.764.4556; E-mail: peterstm@umich.edu. Or to: Carlos H. Serezani, 5501B MSRB I, 1150 W. Medical Center Drive, University of Michigan Health System, Ann Arbor, Michigan 48109-5642, USA. Phone: 734.615.5523; Fax: 734.764.4556; E-mail: cserezan@umich.edu.